GDTC

CytoMed Therapeutics Limited Ordinary Shares
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$13.37M
P/E Ratio
EPS
$-0.27
Beta
-0.17
52W High
$3.68
52W Low
$0.68
50-Day MA
$1.01
200-Day MA
$1.49
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)860,850
Gross Profit (TTM)771,090
EBITDA$-3.85M
Operating Margin-535.00%
Return on Equity-50.30%
Return on Assets-29.30%
Revenue/Share (TTM)$0.07
Book Value$0.43
Price-to-Book2.61
Price-to-Sales (TTM)15.53
EV/Revenue47.73
EV/EBITDA-4.45
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)46.90%
Shares Outstanding$11.83M
Float$3.92M
% Insiders67.83%
% Institutions0.18%

Historical Volatility

HV 10-Day
176.80%
HV 20-Day
167.85%
HV 30-Day
138.48%
HV 60-Day
101.53%
HV Rank
100.0%

Volatility is currently expanding

More HEALTHCARE Stocks

Data last updated: 5/25/2026